New web site launched for practicing urologists

UrologyTrends.com (www.urologytrends.com), an online communitydedicated to providing educational resources to the practicing urologist,is launching this week. The web site is intended to help urologists improvepatient care by providing a convenient forum to expand their knowledge ofkey clinical, economic, and patient management issues.

Related Videos

Related Content

Advertisement

March 26th 2025

RAG-01 elicits complete responses in NMIBC

Hannah Clarke

"The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 26th 2025

Bel-sar shows promising safety, efficacy in NMIBC

Hannah Clarke

In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

March 25th 2025

Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC

Hannah Clarke

"Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.

Related Content

Advertisement

March 26th 2025

RAG-01 elicits complete responses in NMIBC

Hannah Clarke

"The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 26th 2025

Bel-sar shows promising safety, efficacy in NMIBC

Hannah Clarke

In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

March 25th 2025

Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC

Hannah Clarke

"Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.